Hepatitis B Virus (HBV) Global Market Report 2024

The global hepatitis b virus (hbv) market has grown rapidly in recent years. It will grow from $6.04 billion in 2023 to $6.71 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising prevalence of hepatitis b virus (hbv), growing demand for hbv diagnostics, expanding hbv vaccine coverage, rising awareness of hepatitis b virus (hbv).

The global hepatitis b virus (hbv) market is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rise of personalized medicine, growing support from patient advocacy groups, rising vaccination programs, increase in healthcare expenditure. Major trends in the forecast period include development of new drugs, advancements in diagnostic technologies, public-private partnerships, innovative biological therapies.

The heightened prevalence of hepatitis B infection is anticipated to drive the growth of the hepatitis B virus market in the foreseeable future. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), and it can be prevented through vaccination. The increasing rates of hepatitis B infections are likely to result in greater demand for diagnostic tests and treatment options. For example, data from December 2022, sourced from the European Centre for Disease Prevention and Control, an organization based in Sweden dedicated to enhancing Europe's defenses against infectious diseases, revealed that there were 16,187 recorded cases of hepatitis B virus (HBV) infection in 30 Eastern European Member States in 2021. Additionally, the total number of cases, 15,380, corresponded to a crude rate of 4.7 cases per 100,000 people, compared to 14,332 cases in 2020. Consequently, the substantial prevalence of hepatitis B infection is poised to be a driving force behind the hepatitis B virus market's growth.

The rising incidence of patients suffering from liver damage or cirrhosis is expected to drive the growth of the hepatitis B virus market in the future. Cirrhosis is a severe form of liver disease characterized by the permanent replacement of healthy liver tissue with scar tissue. The hepatitis B virus plays a significant role in impacting patients with liver disease by affecting kidney function while mitigating symptoms and adverse effects of the disorder. For instance, according to a Fact Sheet published by the Centers for Disease Control and Prevention in September 2022, there were 4.5 million adults diagnosed with liver disease in the United States. Additionally, data from Medscape, a medical information website, shows that fatalities related to alcoholic liver disease (ALD) increased by 17.6% between 2019 and 2021, while non-alcoholic fatty liver disease (NAFLD)-related deaths rose by 14.5%. As a result, the growing number of patients experiencing liver damage or cirrhosis is fueling the expansion of the hepatitis B virus market.

The growth of the hepatitis B virus (HBV) market in the forecast period may face constraints due to the increasing healthcare expenditure. While HBV screening is considered cost-effective, the rising costs in healthcare could limit the availability of point-of-care hepatitis B surface antigen tests in countries with limited resources. This situation could potentially lead to delays in patient care and reduced access to essential diagnostics. For example, in the UK, healthcare spending increased by 9.4% in nominal terms and 9.7% in real terms between 2020 and 2021. Additionally, preventive care spending more than doubled from 2020 to 2021. Consequently, the upward trend in healthcare expenditure could pose challenges to the growth of the hepatitis B virus (HBV) market in the future.

Prominent companies operating within the hepatitis B virus (HBV) market are placing a strong emphasis on the advancement of cutting-edge diagnostics and treatment options. One such innovation involves the utilization of highly sensitive chemiluminescent microparticle immunoassay (CMIA) technology to gain a competitive edge in the market. A case in point is Abbott Laboratories, a healthcare company based in the United States, which, in May 2022, introduced the HBsAg Next Qualitative Solution Test. This test is designed to facilitate the early detection of the Hepatitis B virus (HBV) in human serum and plasma samples. By enhancing early detection capabilities, this advanced chemiluminescent microparticle immunoassay (CMIA) not only contributes to improved patient outcomes but also safeguards the integrity of blood supplies. It enables both early detection of HBV in human serum and plasma (blood) samples and population screening, all thanks to its highly sensitive technology.

In July 2023, Brii Biosciences Ltd., a biotechnology firm headquartered in China, secured licensing rights for an experimental hepatitis B immunotherapy and an approved hepatitis B vaccine from VBI Vaccines Inc., an American biotechnology company. This transaction, for an undisclosed sum, grants Brii Biosciences Ltd. access to valuable insights related to both the prevention and treatment of hepatitis B. VBI Vaccines Inc. specializes in the development of a vaccine designed to prevent infections caused by the hepatitis B virus.

Major players in the hepatitis b virus (hbv) market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmon La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Eisai Co. Ltd., Aurobindo Pharma Limited, Apotex Corp., Lupin Pharmaceuticals Inc., Cadila Healthcare Ltd., Celltrion Inc., Dynavax Technologies Corporation, Accord Healthcare Inc., Par Pharmaceutical Inc., Arrowhead Pharmaceuticals Inc., Arbutus Biopharma Corporation, Globeimmune Inc., Antios Therapeutics Inc.

North America was the largest region in the hepatitis B Virus (HBV) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis B virus (HBV) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepatitis B virus (HBV) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Hepatitis B virus (HBV) is categorized into acute and chronic forms. Acute hepatitis B is a short-term infection resulting from HBV, typically occurring within the first six months of exposure. The medications for acute cases aim to clear the virus from the body and prevent chronic infection. Treatment options include immune modulator drugs, antiviral medications, vaccines, and, in some cases, surgery. These treatments are administered to individuals across various age groups, including pediatrics, adults, and seniors, with medical providers, patients, and healthcare payers being involved in the healthcare process.

This report provides hepatitis B virus (HBV) market statistics, including hepatitis B virus (HBV) industry global market size, regional shares, competitors with a hepatitis B virus (HBV) market share, detailed hepatitis B virus (HBV) market segments, market trends and opportunities and any further data you may need to thrive in the hepatitis B virus (HBV) industry. This hepatitis B virus (HBV) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis B virus (HBV) market consists of revenues earned by entities by providing diagnostic testing for infection and monitoring of liver function. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis B virus (HBV) market also includes sales of tenofovir disoproxil, entecavir, telbivudine and lamivudine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.